Your browser doesn't support javascript.
A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019.
Shabani, M; Sadegh Ehdaei, B; Fathi, F; Dowran, R.
  • Shabani M; Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Sadegh Ehdaei B; Microbiology and Immunology Department, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
  • Fathi F; Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Dowran R; Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
New Microbes New Infect ; 42: 100895, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1275601
ABSTRACT
Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between hepatitis C virus RNA polymerase and severe acute respiratory syndrome coronavirus 2 has also been established. The efficacy of sofosbuvir and daclatasvir as potential choices in treating patients with coronavirus disease 2019 and their recovery can be hypothesized.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: New Microbes New Infect Year: 2021 Document Type: Article Affiliation country: J.nmni.2021.100895

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: New Microbes New Infect Year: 2021 Document Type: Article Affiliation country: J.nmni.2021.100895